Abstract
Introduction: There have been several reported cases of lansoprazole-associated collagenous colitis (CC) reported in the literature but only 1 reported case of lansoprazole-associated lymphocytic colitis (LC) in the literature. Both CC and LC are considered inflammatory bowel diseases, but they are distinctly classified based on the condition of the colon, which is typically confirmed through biopsy.
Case summaries: A 52-year-old white male (Patient 1), with a height of 178 cm and weight of 75 kg, presented to Gazi University Hospital, Ankara, Turkey, with a 3-month history of abdominal pain and nonbloody, watery diarrhea. The patient reported receiving PO lansoprazole 30 mg/d to treat heartburn ~1 week prior to the onset of diarrhea. The patient's medical history revealed that he did not have any preexisting conditions, other than gastroesophageal reflux disease (GERD) for which lansoprazole was prescribed. The medical history report also revealed that the patient was not receiving any concomitant medications or treatments at the time. A colon biopsy confirmed LC. Additionally, a 43-year-old white female (Patient 2), with a height of 168 cm and weight of 61 kg, presented to the same facility with a 6-month history of nonbloody, watery diarrhea and mild lower abdominal cramping. The patient reported that initial onset began ~2 months after receiving a 10-day Helicobacter pylori eradication combination treatment regimen that included lansoprazole, amoxicillin, and clarithromycin, followed by lansoprazole monotherapy to treat GERD. The patient's medical history revealed no other concomitant medications were being adminstered at the time. A colon biopsy confirmed LC.
Discussion: A search of the literature using the MEDLINE database and all relevant English-language articles with key words lansoprazole and lymphocytic colitis, found that there were several cases of lansoprazole-associated CC reported and 1 reported case of lansoprazole-associated LC. Histologic findings from laboratory tests and colon biopsies confirmed diagnoses of LC in both patients in this case report. Patient 1 presented with diarrhea and cramping, which the patient reported had been ongoing for ~3 months, following lansoprazole administration. However, after lansoprazole was discontinued, the symptoms completely resolved within 7 days. Patient 2 presented with diarrhea and cramping, which had been occurring for ~6 months. That patient reported that initial onset commenced ~2 months after a 10-day H pylori eradication combination treatment regimen that included lansoprazole, amoxicillin, and clarithromycin, followed by lansoprazole monotherapy to treat GERD. However, after sulfasalazine (3 g/d) was prescribed for 2 months immediately upon diagnosis of LC, there was little improvement in the effort to control the diarrhea in this patient. After omeprazole 20 mg/d was substituted for lansoprazole, the patient's diarrhea ceased. Follow-up sigmoidoscopy 2 months later revealed normal mucosa and complete normalization of histologic findings. The patient remains diarrhea-free while on omeprazole. A causality assessment using the Naranjo adverse reaction algorithm produced scores of 6 for both patients, suggesting that LC was probably associated with lansoprazole treatment.
Conclusions: Here we report 2 cases of LC in patients probably associated with the administration of lansoprazole treatment. Complete remission occurred after lansoprazole was discontinued.
Key words: lansoprazole, microscopic colitis, gastroesophageal reflux disease
Full Text
The Full Text of this article is available as a PDF (446.5 KB).
References
- 1.Matheson AJ, Jarvis B. Lansoprazole: An update of its place in the management of acid-related disorders. Drugs. 2001;61:1801–1833. doi: 10.2165/00003495-200161120-00011. [DOI] [PubMed] [Google Scholar]
- 2.Fiedorek S, Tolia V, Gold BD. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2005;40:319–327. doi: 10.1097/01.mpg.0000155369.54464.41. [DOI] [PubMed] [Google Scholar]
- 3.Leufkens H, Claessens A, Heerdink E. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther. 1997;11:887–897. doi: 10.1046/j.1365-2036.1997.00214.x. [DOI] [PubMed] [Google Scholar]
- 4.Claessens AA, Heerdink ER, van Eijk JT. Characteristics of diarrhea in 10,008 users of lansoprazole in daily practice: Which co-factors contribute. Pharmacoepidemiol Drug Saf. 2002;11:703–708. doi: 10.1002/pds.769. [DOI] [PubMed] [Google Scholar]
- 5.Lazenby AJ, Yardley JH, Giardiello FM. Lymphocytic (“microscopic”) colitis: A comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol. 1989;20:18–28. doi: 10.1016/0046-8177(89)90198-6. [DOI] [PubMed] [Google Scholar]
- 6.Liszka L, Woszczyk D, Pajak J. Histopathological diagnosis of microscopic colitis. J Gastroenterol Hepatol. 2006;21:792–797. doi: 10.1111/j.1440-1746.2006.04332.x. [DOI] [PubMed] [Google Scholar]
- 7.Fernandez-Banares F, Salas A, Esteve M. Collagenous and lymphocytic colitis: Evaluation of clinical and histological features, response to treatment, and longterm follow-up. Am J Gastroenterol. 2003;98:340–347. doi: 10.1111/j.1572-0241.2003.07225.x. [DOI] [PubMed] [Google Scholar]
- 8.Jawhari A, Talbot IC. Microscopic, lymphocytic and collagenous colitis. Histopathology. 1996;29:101–110. doi: 10.1046/j.1365-2559.1996.d01-498.x. [DOI] [PubMed] [Google Scholar]
- 9.Read NW, Krejs GJ, Read MG. Chronic diarrhea of unknown origin. Gastroenterology. 1980;78:264–271. [PubMed] [Google Scholar]
- 10.Tagkalidis P, Bhathal P, Gibson P. Microscopic colitis. J Gastroenterol Hepatol. 2002;17:236–248. doi: 10.1046/j.1440-1746.2002.02640.x. [DOI] [PubMed] [Google Scholar]
- 11.Fernandez-Banares F, Esteve M, Espinos JC. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007;102:324–330. doi: 10.1111/j.1572-0241.2006.00902.x. [DOI] [PubMed] [Google Scholar]
- 12.Olesen M, Eriksson S, Bohr J. Lymphocytic colitis: A retrospective clinical study of 199 Swedish patients. Gut. 2004;53:536–541. doi: 10.1136/gut.2003.023440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Beaugerie L, Pardi DS. Review article: Drug-induced microscopic colitis—proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005;22:277–284. doi: 10.1111/j.1365-2036.2005.02561.x. [DOI] [PubMed] [Google Scholar]
- 14.Beaugerie L, Patey N, Brousse N. Ranitidine, diarrhoea, and lymphocytic colitis. Gut. 1995;37:708–711. doi: 10.1136/gut.37.5.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Duncan HD, Talbot IC, Silk DB. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol. 1997;9:819–820. doi: 10.1097/00042737-199708000-00016. [DOI] [PubMed] [Google Scholar]
- 16.Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: A case-control study. Gut. 1992;33:683–686. doi: 10.1136/gut.33.5.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Giardiello FM, Hansen FC., III Collagenous colitis in setting of nonsteroidal antiinflammatory drugs and antibiotics. Dig Dis Sci. 1990;35:257–260. doi: 10.1007/BF01536772. [DOI] [PubMed] [Google Scholar]
- 18.Chagnon JP, Cerf M. Simvastatin-induced protein-losing enteropathy. Am J Gastroenterol. 1992;87:257. [PubMed] [Google Scholar]
- 19.Berrebi D, Sautet A, Flejou JF. Ticlopidine induced colitis: A histopathological study including apoptosis. J Clin Pathol. 1998;51:280–283. doi: 10.1136/jcp.51.4.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Chauveau E, Prignet JM, Carloz E. Lymphocytic colitis likely attributable to use of vinburnine (Cervoxan) [in French] Gastroenterol Clin Biol. 1998;22:362. [PubMed] [Google Scholar]
- 21.Bouchet-Laneuw F, Deplaix P, Dumollard JM. Chronic diarrhea following ingestion of Tardyferon associated with lymphocytic colitis [in French] Gastroenterol Clin Biol. 1997;21:83–84. [PubMed] [Google Scholar]
- 22.Wilcox GM, Mattia A. Collagenous colitis associated with lansoprazole. J Clin Gastroenterol. 2002;34:164–166. doi: 10.1097/00004836-200202000-00013. [DOI] [PubMed] [Google Scholar]
- 23.McJunkin B, Fromm H, Sarva RP, Amin P. Factors in the mechanism of diarrhea in bile acid malabsorption: Fecal pH—a key determinant. Gastroenterology. 1981;80:1454–1464. [PubMed] [Google Scholar]
- 24.Zins BJ, Sandborn WJ, Tremaine WJ. Collagenous and lymphocytic colitis: Subject review and therapeutic alternatives. Am J Gastroenterol. 1995;90:1394–1400. [PubMed] [Google Scholar]
- 25.Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272:22438–22446. doi: 10.1074/jbc.272.36.22438. [DOI] [PubMed] [Google Scholar]
- 26.Kaunitz JD, Gunther R, Wright EM. Involvement of multiple sodium ions in intestinal d-glucose transport. Proc Natl Acad Sci US A. 1982;79:2315–2318. doi: 10.1073/pnas.79.7.2315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245. doi: 10.1038/clpt.1981.154. [DOI] [PubMed] [Google Scholar]